Short answer
CERUS CORP (CERS) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $57M with net income of −$3M.
Q2 2026 key financials · XBRL
- Revenue
- $57M
- +7.0% QoQ
- Net income
- −$3M
- +48.5% YoY · −79.3% QoQ
- Operating margin
- -3.2%
- EPS (diluted)
- −$0.01
- +66.7% YoY · +0.0% QoQ
Source: XBRL data from the CERUS CORP (CERS) Q2 2026 10-Q on SEC EDGAR. USD.
CERUS CORP Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- IFC kit sales accelerating, shifting toward blood-center customers
- BARDA agreements extended through March 2027 and September 2031
- RedeS trial completion anticipated second half of 2026; additional clinical data required before PMA discussions
Risk Factors
- Newly triggered risk: U.S. platelet shortages may reduce INTERCEPT adoption as hospitals prioritize product availability over pathogen-reduction preferences
- Regulatory risk: FDA has not granted a seven-day storage claim for INTERCEPT-treated platelets, potentially driving customers toward competing solutions
- Operational risk: Mishandling after treatment has introduced environmental bacteria, requiring heightened blood-center handling controls
- Market concentration risk: American Red Cross represents the largest U.S. blood-collection share and currently cannot produce IFC for its own accounts
- Financial risk: BARDA funding reductions, delays, or milestone disputes could significantly reduce government-contract revenue and cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CERUS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.